CRISPR Therapeutics AG (NASDAQ: CRSP) kicked off on Friday, up 14.33% from the previous trading day, before settling in for the closing price of $43.49. Over the past 52 weeks, CRSP has traded in a range of $36.52-$91.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 31550.17% over the last five years. While this was happening, its average annual earnings per share was recorded -8.74%. With a float of $82.09 million, this company’s outstanding shares have now reached $85.74 million.
The firm has a total of 393 workers. Let’s measure their productivity. In terms of profitability, gross margin is -227.47%, operating margin of -1273.97%, and the pretax margin is -990.27%.
CRISPR Therapeutics AG (CRSP) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of CRISPR Therapeutics AG is 4.30%, while institutional ownership is 69.46%. The most recent insider transaction that took place on Dec 02 ’24, was worth 826,564. In this transaction Chief Executive Officer of this company sold 15,000 shares at a rate of $55.10, taking the stock ownership to the 181,540 shares. Before that another transaction happened on Nov 11 ’24, when Company’s Chief Executive Officer sold 30,000 for $55.62, making the entire transaction worth $1,668,678. This insider now owns 196,540 shares in total.
CRISPR Therapeutics AG (CRSP) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -8.74% per share during the next fiscal year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Take a look at CRISPR Therapeutics AG’s (CRSP) current performance indicators. Last quarter, stock had a quick ratio of 22.07. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 114.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.36, a number that is poised to hit -1.22 in the next quarter and is forecasted to reach -3.87 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
Analysing the last 5-days average volume posted by the [CRISPR Therapeutics AG, CRSP], we can find that recorded value of 3.5 million was better than the volume posted last year of 2.21 million. As of the previous 9 days, the stock’s Stochastic %D was 84.23%. Additionally, its Average True Range was 2.65.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 58.54%, which indicates a significant decrease from 79.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.01% in the past 14 days, which was higher than the 55.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $42.73, while its 200-day Moving Average is $49.52. Now, the first resistance to watch is $52.87. This is followed by the second major resistance level at $56.01. The third major resistance level sits at $59.43. If the price goes on to break the first support level at $46.31, it is likely to go to the next support level at $42.89. Now, if the price goes above the second support level, the third support stands at $39.75.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
The company with the Market Capitalisation of 4.26 billion has total of 85,774K Shares Outstanding. Its annual sales at the moment are 371,210 K in contrast with the sum of -153,610 K annual income. Company’s last quarter sales were recorded 600 K and last quarter income was -85,940 K.
